Edwards Lifesciences (EW) PT Raised to $186 at Raymond James
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Edwards Lifesciences (EW) PT Raised to $190 at Canaccord Genuity
February 1, 2019 7:29 AM ESTCanaccord Genuity analyst Jason Mills raised the price target on Edwards Lifesciences (NYSE: EW) to $190.00 (from $186.00) while maintaining a Buy rating.
... MoreEdwards Lifesciences (EW) PT Raised to $190 at BMO Capital
February 1, 2019 7:23 AM ESTBMO Capital analyst Joanne Wuensch raised the price target on Edwards Lifesciences (NYSE: EW) to $190.00 (from $182.00) while maintaining a Outperform rating.
... MoreEdwards Lifesciences (EW) PT Raised to $175 at UBS
February 1, 2019 7:15 AM ESTUBS analyst Matthew Taylor raised the price target on Edwards Lifesciences (NYSE: EW) to $175.00 (from $165.00) while maintaining a Neutral rating.
... MoreEdwards Lifesciences (EW) PT Raised to $182 at RBC Capital
February 1, 2019 6:42 AM ESTRBC Capital analyst Glenn Novarro raised the price target on Edwards Lifesciences (NYSE: EW) to $182.00 (from $175.00) while maintaining a Outperform rating.
Novarro commented, "Revenue guidance for 1Q19, implying high-single-digit CC growth at the midpoint, adequately captures competitive dynamics in the TAVR market.... More
Edwards Lifesciences (EW) Reports In-Line Q4 EPS, Q1 EPS Guidance Comes in Light
January 31, 2019 4:19 PM ESTEdwards Lifesciences (NYSE: EW) reported Q4 EPS of $1.17, in-line with the analyst estimate of $1.17. Revenue for the quarter came in at $978 million versus the consensus estimate of $975.92 million.
GUIDANCE:
Edwards Lifesciences sees Q1 2019 EPS of $1.15-$1.25, versus the consensus of $1.30.... More
